CCR5 receptor antagonist

The life cycle of HIV presents potential targets for drug therapy, one of them being the viral entry pathway. The C-C motif chemokine receptors CCR5 and CXCR4 are the main chemokine receptors involved in the HIV entry process. These receptors belong to the seven transmembrane G-protein-coupled receptor (GPCR) family and are predominantly expressed on human T-cells, dendritic cells and macrophages. They play an important role as co-receptors that HIV type 1 (HIV-1) uses to attach to cells before viral fusion and entry into host cells. HIV isolates can be divided into R5 and X4 strains. R5 strain is when the virus uses the co-receptor CCR5 and X4 strain is when it uses CXCR4. The location of CCR5 receptors at the cell surface, both large and small molecules have the potential to interfere with the CCR5-viral interaction and inhibit viral entry into human cells. The following summarizes the discovery and development of small molecule antagonists of CCR5 receptor.

History

Since the discovery of HIV in the 1980’s, remarkable progress has been made in the development of novel antiviral drugs. What triggered the discovery of the CCR5 antagonists was the observation that a small percentage of high-risk populations showed either resistance or delayed development of the disease. Normal 0 21 false false false IS X-NONE X-NONE They found out that this population had a mutation (CCR5-Δ32) in the gene that codes for the CCR5 receptor which results in almost complete resistance against HIV-1 infection. Followed by that detection scientists discovered the key role of the cell surface receptors CCR5 and CXCR4 in successful viral fusion and infection. In 1996, it was demonstrated that CCR5 serves as a co-receptor for the most commonly transmitted HIV-1 strains, R5. That type of virus is predominate during the early stages of infection and remain the dominant form in over 50% of late stage HIV-1 infected patients, however R5 strains can eventually evolve into X4 as the disease progresses. This information led to the development of a new class of HIV drugs called CCR5 antagonists.

Mechanism of action

Figure 1 HIV entry into CD4+ cell via CCR5 co-receptor.

HIV enters host cells in the blood by attaching itself to receptors on the surface of the CD4+ cell. Viral entry to the CD4+ cell begins with attachment of the R5 HIV-1 glycoprotein 120 (gp120) to the CD4+ T-cell receptor, which produces a conformational change in gp120 and allows it to bind to CCR5, thereby triggering glycoprotein 41 (gp41) mediated fusion of the viral envelope with the cell membrane and the nucleocapsid enters the host cell (Figure 1). CCR5 co-receptor antagonists prevent HIV-1 from entering and infecting immune cells by blocking CCR5 cell-surface receptor. Small molecule antagonists of CCR5 bind to a hydrophobic pocket formed by the transmembrane helices of the CCR5 receptor. They are thought to interact with the receptor in an allosteric manner locking the receptor in a conformation that prohibits its co-receptor function.

Drug development

As mentioned, the CCR5 receptor is a G-protein coupled receptor (GPRC) and before the discovery of CCR5’s role in HIV infection many pharmaceutical companies had already built a substantial collection of compounds that target GPRCs. Some of these compounds provided an excellent starting point for CCR5 antagonists. These compounds then needed further optimization to gain better potency, pharmacokinetic properties and better CCR5 selectivity. One of their biggest problems was the affinity for the hERG ion channel, as inhibition of hERG can lead to QT interval prolongation. Abnormality in the interval can increase the risk of developing ventricular arrhythmias. Many CCR5 antagonists have been introduced by pharmaceutical companies but few of them have actually reached human efficacy studies. For example AstraZeneca, Novartis, Merck and Takeda have used these GPRC compound collections to develop a potent CCR5 antagonist but none of them have reached clinical trials. Three pharmaceutical companies were racing for the first approved small molecule CCR5 antagonist. They were GlaxoSmithKline(GSK), with their compound aplaviroc, Schering-Plough with vicriviroc and Pfizer with maraviroc. All these compounds reached clinical trials in humans but only maraviroc has been approved by the FDA, but it was approved in August 2007. In the following section the development of these three compounds will be discussed.

Aplaviroc

File:Brynja 1ba.png

Figure 2 Molecular structure of aplaviroc and its lead compound

File:Brynja3 copy.PNG

Figure 3 Molecular structure of vicriviroc and its lead compounds

Template:FixBunching Aplaviroc is originated from a class of spirodiketopiperazine derivatives. Figure 2 shows the molecular structure of the lead compound and the final compound aplaviroc. The lead compound showed good potency in blocking CCR5 in a number of R5 HIV strains and against multi-drug resistant strains. The problem with this compound was not its CCR5 selectivity but the oral bioavailability. This led to further development of the molecule and the result was a compound named aplaviroc. Unfortunately despite the promising preclinical and early clinical results some severe liver toxicity was observed in the treatment of naive and treatment-experienced patients that led to the discontinuation in further development of aplaviroc.

Vicriviroc

Schering-Plough identified an active compound during screening. Figure 3 shows the molecular structure of the lead compound, intermediate compound and the final compound vicriviroc. The lead compound contained a piperazine scaffold and was a potent muscarinic acetylcholine receptor (M2) antagonist with modest CCR5 activity. The changes that were made on the left hand side of the lead compound and the addition of a methyl group on the piperazine group ((S)-methylpiperazine) resulted in the intermediate compound that had good affinity for CCR5 receptors but very little affinity for muscarinic activity. However the compound did show affinity for the hERG ion channel. Further reconstruction led to the development of the final compound vicriviroc, when Schering discovered that the pyridyl N-oxide on the intermediate could be replaced by 4,6-dimethylpyrimidine carboxamide. Vicriviroc had an excellent selectivity for CCR5 receptors over muscarinic and hERG affinity was greatly reduced. Phase I clinical trial of vicriviroc gave promising results so a phase II study in the treatment of naive patients was initiated. The phase II study was discontinued since there was a viral breakthrough in the vicriviroc group compared to the control group. These results suggested that vicriviroc was not effective in the treatment of treatment-naive patients compared to current treatments. Another phase II clinical study was performed in treatment-experienced patients. The results were that vicriviroc did have strong antiviral activity but five instances of cancer among the participants were reported. However, the study was continued since there was lack of causal association of the malignancies and vicriviroc. In late 2009 vicriviroc was assigned in phase III studies in treatment-experienced patients, and in phase II studies in treatment for naive patients.

Maraviroc

Pfizer turned to high-throughput screening in their search for a good starting point for a small molecule CCR5 antagonist. Their screening resulted in a compound that presented weak affinity and no antiviral activity but represented a good starting point for further optimization. Compounds 1-9 in table 1 show the development of maraviroc in few steps. Their first focus was to minimize CYP2D6 activity of the molecule and to reduce its lipophilicity. They replaced the imidazopyridine with benzimidazol and the benzhydril group was swapped out for a benzamide. The outcome was compound 2. That compound showed good binding potency and the start of an antiviral activity. Further SAR (structure-activity relationship) optimization of the amide region and identifying the enantiomeric preference led to the cyclobutyl amide structure in compound 3. However, the problem with the CYP2D6 activity of the compound was still unacceptable so they had to perform further SAR optimization that determined that the [3.2.1]-azabicycloamine (tropane) could replace the aminopiperidine moiety. This change in the chemical structure led to compound 4. Compound 4 had no CYP2D6 activity while preserving excellent binding affinity and antiviral activity. Although compound 4 showed promising results it demonstrated 99% inhibition on the hERG ion channel. That inhibition was unacceptable since it can lead to QT interval prolongation. The research team then did a few modifications to see which part of the molecule played a role in the hERG affinity. Compound 5 shows an analogue that they synthesized which contained an oxygen bridgehead in the tropane ring; however, that reconstruction did not have an effect on the hERG affinity. Then they focused on the polar surface area in the molecule to dial out the hERG affinity. These efforts resulted in compound 6. That compound preserved desired antiviral activity and was selective against the hERG inhibition but the problem was its bioavailability. Reduction in the lipophilicity, by replacing the benzimidazol group with a substituted triazole group gave compound 7. That molecule showed a significant reduction in lipophilicity and maintained the antiviral activity but again with the introduction of a cyclobutyl group the compound showed hERG inhibition. Changing the ring size in compound 7 from a cyclobutyl unit to a cyclopentyl unit in compound 8 led to a significant increase in antiviral activity and loss of hERG affinity. Further development led to discovery of a 4,4’-difluorocyclohexylamide also known as maraviroc, which preserved excellent antiviral activity, whilst demonstrating no significant hERG binding affinity. The lack of hERG binding affinity was predictive to be because of the large size of the cyclohexyl group and the high polarity of the fluoro substituents.

Table 1 Represents the molecular structures in the development of maraviroc

File:Fyrstikassi.png
Compound 1	Compound 2	Compound 3
Compound 4	Compound 5	Compound 6
Compound 7	Compound 8	Compound 9 (Maraviroc)

Binding

The structure of the CCR5 receptor comprises of seven-helix bundle in the transmembrane region, these regions are labeled I-VII in figure 4 and 5. The CCR5 antagonists are predicted to bind to a putative binding pocket which is buried inside the transmembrane domain, enclosed by the seven transmembrane helices. The binding pocket is very hydrophobic with multiple aromatic residues lining the pocket. The key residues are tryptophan 86 and 248 (Trp86, Trp248), tyrosine 108 and 251 (Tyr108, Tyr251), phenylalanine 109 (phe109), threonine 195 (Thr195), isoleucine 198 (Ile198), glutamic acid 283 (Glu283). CCR5 antagonists are very different in shape and electrostatic potential although they all share the same binding pocket. The interesting thing about the binding of these molecules is that significant difference in binding modes although they all establish an extensive interaction network with CCR5.

Binding of aplaviroc

Figure 4 Putative binding of aplaviroc to the CCR5 receptor

Figure 5 Putative binding of maraviroc to the CCR5 receptor

Template:FixBunching The putative binding mode for maraviroc is shown in figure 4. The key saltbridge interaction between aplaviroc and Glu283 is predicted to be quite weak compared to other CCR5 antagonists. The hydroxyl group on aplaviroc forms a strong hydrogen bond to the polar residue Thr195. This H-bond interaction is the strongest with aplaviroc compared to other CCR5 antagonists. The cyclohexyl group in the aplaviroc structure is predicted to interact with the receptor in a hydrophobic pocket formed by Ile198, Thr15 and Phe109 and is thought to be quite strong hydrophobic interactions. The researcher predict that the t-butyl group of aplaviroc is buried within the helical bundle through strong hydrophobic interaction with multiple aromatic residues of the CCR5 receptor.

[[Image:Brynja3.PNG‎ ‎‎

|thumb|350px|right|Figure 4 Putative binding of aplaviroc to the CCR5 receptor]]

Binding of maraviroc

The putative binding mode for maraviroc is shown in figure 5. The strongest interaction is estimated to be between maraviroc and glutamic acid (Glu283) through a strong salt-bridge interaction. The interaction between tryptophan (Trp86) and maraviroc involves T-shaped π-π stacking while the interaction with phenylalanine (Phe109) is predicted to be hydrophopic. Tyrosine (Tyr108) is thought to interact with the phenyl group on maraviroc through a parallel displaced interaction. The interaction between maraviroc and isoleucine (Ile198) is predicted to be mostly hydrophobic in nature and the interaction between maraviroc and tyrosine (Tyr251) is very limited.

Unique binding of aplaviroc

Aplaviroc has a unique feature of preserving two of the natural chemokine protein ligands binding to CCR5 and subsequent activation whereas maraviroc and the other antagonists almost fully block chemokine-CCR5 interactions. This kind of interference is so far considered to be safe and individuals that naturally lack CCR5 do not show any obvious health problems. However, to limit the toxicity and side effects of CCR5 antagonists it would be ideal to be able to preserve the chemokine receptor function. Consequently, it should be of interest to design inhibitors that specifically disrupt CCR5-gp120 binding but do not affect the CCR5 chemokine activation.

Future developments in CCR5 receptors

Figure 6 Molecular structure of compound A

Template:FixBunching Development of new CCR5 antagonists continues, both for their antiviral effects and also for potential utility in a variety of autoimmune indications. Researchers at Ono have discovered a novel series of potent CCR5 small molecule antagonists. Lead optimization was pursued by balancing opposing trends of metabolic stability and potency. Combination of the spiropiperidine template with pharmacophore elements from both aplaviroc and Schering’s CCR5 antagonist program led to the initial lead compound in this series. Further development of that lead compound led to the discovery of compound A in figure 6. A compound that possesses a good selectivity and pharmacokinetic properties.

The CCR5 antagonist INCB009471 has nanomolar activity against HIV-1 in vitro. This compound demonstrated potent and prolonged antiviral activity against R5-tropic HIV-1 when given 200 mg once daily dose for 14 days. These findings support further clinical development of INCB009471. It has progressed to phase IIb clinical trials. In 2009 the study of this compound is inactive and no further studies are planned at this time.

See also

• CCR5
• CXCR4
• HIV
• Antiviral drugs
• G protein-coupled receptor
• AIDS
• gp41
• Entry inhibitor
• maraviroc
• CD4
• CCL5
• Subtypes of HIV
• HIV tropism